Efficacy and Safety of a Transdermal Carbon Dioxide-Releasing Gel for the Treatment of Genitourinary Syndrome in Vulvar Cancer Survivors: A Prospective Pilot Study

Introduction: Genitourinary syndrome of menopause (GSM) is a major sequela in women with a history of vulvar cancer, exacerbated by surgical and radiotherapy treatments that compromise the anatomy and function of the lower genital tract. Hormonal therapeutic options are often limited in this population due to oncologic risks (1,2,7,8), emphasizing the need for safe and effective alternatives. In this context, transdermal carbon dioxide (CO₂)- releasing gels have demonstrated beneficial effects on microcirculation, tissue oxygenation, and cellular regeneration (23–29), offering an innovative non-hormonal strategy for managing vulvovaginal symptoms in cancer survivors. Objective: To evaluate the progression of vulvoperineal symptoms in patients with a history of vulvar cancer undergoing regenerative therapy. Materials and Methods: Five patients diagnosed with GSM were included. Regenerative treatment was applied, and 15 symptoms were evaluated at baseline, 6 weeks, and 3 months. Results: The mean total symptom burden decreased from 14.4 at baseline to 10.0 at 6 weeks, and to 0.8 at 3 months (94.4% reduction). Although paired comparisons did not reach statistical significance (p=0.0625), effect size measures (ARR and RRR) indicated clinically meaningful improvement in most symptoms. Conclusion: The regenerative protocol produced marked and sustained clinical improvement in GSM symptoms in patients with a history of vulvar cancer. Studies with larger sample sizes are warranted to confirm statistical significance. Keywords: Genitourinary syndrome, carbon dioxide-releasing transdermal gel, regenerative therapies, vulvar cancer survivors.

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-20
DOI
https://doi.org/10.5281/zenodo.24419251
Primary Topic
Menopause: Health Impacts and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy and Safety of a Transdermal Carbon Dioxide-Releasing Gel for the Treatment of Genitourinary Syndrome in Vulvar Cancer Survivors: A Prospective Pilot Study

Gustavo H. Leibaschoff, Javier Enrique Serrano Ramos, Marta Serrano Ramos
Zenodo (CERN European Organization for Nuclear Research)
Menopause: Health Impacts and Treatments
article

Efficacy and Safety of a Transdermal Carbon Dioxide-Releasing Gel for the Treatment of Genitourinary Syndrome in Vulvar Cancer Survivors: A Prospective Pilot Study

Gustavo H. Leibaschoff, Javier Enrique Serrano Ramos, Marta Serrano Ramos
article en

Abstract

Introduction: Genitourinary syndrome of menopause (GSM) is a major sequela in women with a history of vulvar cancer, exacerbated by surgical and radiotherapy treatments that compromise the anatomy and function of the lower genital tract. Hormonal therapeutic options are often limited in this population due to oncologic risks (1,2,7,8), emphasizing the need for safe and effective alternatives. In this context, transdermal carbon dioxide (CO₂)- releasing gels have demonstrated beneficial effects on microcirculation, tissue oxygenation, and cellular regeneration (23–29), offering an innovative non-hormonal strategy for managing vulvovaginal symptoms in cancer survivors. Objective: To evaluate the progression of vulvoperineal symptoms in patients with a history of vulvar cancer undergoing regenerative therapy. Materials and Methods: Five patients diagnosed with GSM were included. Regenerative treatment was applied, and 15 symptoms were evaluated at baseline, 6 weeks, and 3 months. Results: The mean total symptom burden decreased from 14.4 at baseline to 10.0 at 6 weeks, and to 0.8 at 3 months (94.4% reduction). Although paired comparisons did not reach statistical significance (p=0.0625), effect size measures (ARR and RRR) indicated clinically meaningful improvement in most symptoms. Conclusion: The regenerative protocol produced marked and sustained clinical improvement in GSM symptoms in patients with a history of vulvar cancer. Studies with larger sample sizes are warranted to confirm statistical significance. Keywords: Genitourinary syndrome, carbon dioxide-releasing transdermal gel, regenerative therapies, vulvar cancer survivors.

Zenodo (CERN European Organization for Nuclear Research)
Universidad del Centro del Bajío (MX)
Menopause: Health Impacts and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Efficacy and Safety of a Transdermal Carbon Dioxide-Releasing Gel for the Treatment of Genitourinary Syndrome in Vulvar Cancer Survivors: A Prospective Pilot Study — Gustavo H. Leibaschoff, Javier Enrique Serrano Ramos, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS